Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies

NCT04785287 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04785287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Anti-CTLA4-NF mAb (BMS-986218) in Combination With Nivolumab and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
March 29, 2021
Completion date
February 26, 2026
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung carcinoma, advanced malignant solid neoplasm, malignant adrenal gland neoplasm, metastatic liver carcinoma, metastatic lung carcinoma, metastatic malignant solid neoplasm, stage iii liver cancer, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8, stage iv liver cancer, stage iv lung cancer ajcc v8, stage iva liver cancer, stage iva lung cancer ajcc v8, stage ivb liver cancer, stage ivb lung cancer ajcc v8